Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prucalopride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 9/20 | 0.98 |
| ▸ | HTR1A | P08908 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | ACHE | P22303 | 1/20 | 0.98 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | HTR3A | P46098 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prucalopride SCHEMBL16952 | 0.99 | HTR4 (1.00) | HTR4HTR1AADRA2CACHEPTGS1 | |
| Prucalopride SCHEMBL28260565 | 0.98 | HTR4 (0.98) | HTR4HTR1AADRA2CACHEPTGS1 | |
| Prucalopride SCHEMBL7970517 | 0.98 | HTR4 (0.98) | HTR4HTR1AADRA2CACHEPTGS1 | |
| Prucalopride SCHEMBL7960440 | 0.98 | HTR4 (0.98) | HTR4HTR1AADRA2CACHEPTGS1 | |
| Prucalopride SCHEMBL7426504 | 0.96 | HTR4 (0.95) | HTR4HTR1AADRA2CACHEPTGS1 | |
| Prucalopride SCHEMBL7972121 | 0.96 | HTR4 (0.95) | HTR4HTR1AADRA2CACHEPTGS1 | |
| Prucalopride SCHEMBL27531479 | 0.96 | HTR4 (0.93) | HTR4HTR1AADRA2CACHEPTGS1 | |
| Prucalopride SCHEMBL7972080 | 0.96 | HTR4 (0.93) | HTR4HTR1AADRA2CACHEPTGS1 | |
| Prucalopride SCHEMBL7971609 | 0.96 | HTR4 (0.93) | HTR4HTR1AADRA2CACHEPTGS1 | |
| Prucalopride SCHEMBL1230437 | 0.95 | HTR4 (0.92) | HTR4HTR1AADRA2CACHEPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115916174-A | Compositions and methods for preventing stress-induced phobia, depression-like, and anxiety-like behaviors | 纽约市哥伦比亚大学理事会 | 2023-04-04 | — | — | CN | claimed |
| CN-113924087-A | Prophylactic efficacy of serotonin 4receptor agonists against stress | 纽约市哥伦比亚大学理事会 | 2022-01-11 | — | — | CN | claimed |
| US-6310077-B1 | ALKYLATING SUBSTITUTED BENZOFURANCARBOXAMIDE WITH 1-CHLORO-3-METHOXYPROPANE IN SOLVENT IN PRESENCE OF BASE OR ACYLATING 1-(3-METHOXYPROPYL)-4-PIPERIDINAMINE WITH SUBSTITUTED BENZOFURANCARBOXYLIC ACID, FORMING SALT IF DESIRED | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-10-30 | — | — | US | claimed |
| EP-0807110-A1 | ENTEROKINETIC BENZAMIDE | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-11-19 | — | — | EP | claimed |
| WO-1996016060-A1 | ENTEROKINETIC BENZAMIDE | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-05-30 | — | — | WO | claimed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| EP-3413891-B1 | PROCESSES FOR THE PREPARATION OF HIGHLY PURE PRUCALOPRIDE SUCCINATE | SYMED LABS LTD (IN) | 2024-01-03 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| CN-115916174-A | Compositions and methods for preventing stress-induced phobia, depression-like, and anxiety-like behaviors | 纽约市哥伦比亚大学理事会 | 2023-04-04 | — | — | CN | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| WO-2011012715-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | disclosed |
| US-20090170899-A1 | Stimulators of 5-HT4 receptors and uses thereof | MCGILL UNIVERSITY (CA) | 2009-07-02 | — | — | US | disclosed |
| US-20090124592-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING A PATHOLOGY ASSOCIATED WITH AN OBSESSIONAL BEHAVIOR OR WITH OBESITY | CENTRE NAT DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-05-14 | — | — | US | disclosed |
| US-20060116341-A1 | Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS, AN ORGANIZATION OF FRANCE (FR) | 2006-06-01 | — | — | US | disclosed |
| WO-2006029520-A1 | STIMULATORS OF 5-HT4 RECEPTORS AND USES THEREOF | MCGILL UNIVERSITY (CA) | 2006-03-23 | — | — | WO | disclosed |
| US-6310077-B1 | ALKYLATING SUBSTITUTED BENZOFURANCARBOXAMIDE WITH 1-CHLORO-3-METHOXYPROPANE IN SOLVENT IN PRESENCE OF BASE OR ACYLATING 1-(3-METHOXYPROPYL)-4-PIPERIDINAMINE WITH SUBSTITUTED BENZOFURANCARBOXYLIC ACID, FORMING SALT IF DESIRED | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-10-30 | — | — | US | disclosed |
| EP-0807110-A1 | ENTEROKINETIC BENZAMIDE | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-11-19 | — | — | EP | disclosed |
| WO-1996016060-A1 | ENTEROKINETIC BENZAMIDE | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | HTR4 4110/4885HTR1A 4232/4885ADRA2C 4224/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | HTR4 3391/4885HTR1A 2677/4885ADRA2C 884/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | HTR4 4110/4885HTR1A 4232/4885ADRA2C 4224/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | HTR4 3391/4885HTR1A 2677/4885ADRA2C 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.